A phase II, double-blind, randomised placebo-controlled trial of EpiCept NP-1 topical cream in patients with chemotherapy-induced peripheral neuropathy.

Trial Profile

A phase II, double-blind, randomised placebo-controlled trial of EpiCept NP-1 topical cream in patients with chemotherapy-induced peripheral neuropathy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2011

At a glance

  • Drugs Amitriptyline/ketamine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 07 Feb 2011 Positive preliminary results reported in an EpiCept media release.
    • 07 Feb 2011 Primary endpoint 'Pain-intensity' has been met, as reported in an EpiCept media release.
    • 11 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top